Pharmafile Logo
Pharmafocus logo
Advanced Search

cardiovascular events

Showing 1 posts of 1 posts found.

lilly_building_with_american_flag_web

Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes

November 7, 2018
Research and Development Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes

Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025